JP2010532312A - １−ｈ−ピラゾロ（３，４ｂ）ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用 - Google Patents

１−ｈ−ピラゾロ（３，４ｂ）ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用 Download PDF

Info

Publication number
JP2010532312A
JP2010532312A JP2009548293A JP2009548293A JP2010532312A JP 2010532312 A JP2010532312 A JP 2010532312A JP 2009548293 A JP2009548293 A JP 2009548293A JP 2009548293 A JP2009548293 A JP 2009548293A JP 2010532312 A JP2010532312 A JP 2010532312A
Authority
JP
Japan
Prior art keywords
group
pyrazolo
pyrimidin
phenyl
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009548293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532312A5 (enExample
Inventor
スリニバス ラオ カシバトラ，
ケビン ホン，
リン チャン，
マーカス エフ． ベーム，
チュンホア ファン，
ブラジィデック， ジャン−イブ ル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2010532312A publication Critical patent/JP2010532312A/ja
Publication of JP2010532312A5 publication Critical patent/JP2010532312A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009548293A 2007-01-30 2008-01-30 １−ｈ−ピラゾロ（３，４ｂ）ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用 Withdrawn JP2010532312A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89838207P 2007-01-30 2007-01-30
US89830007P 2007-01-30 2007-01-30
PCT/US2008/001230 WO2008094602A2 (en) 2007-01-30 2008-01-30 1-h-pyrazolo (3,4b) pyrimidine derivatives and their use as modulators of mitotic kinases

Publications (2)

Publication Number Publication Date
JP2010532312A true JP2010532312A (ja) 2010-10-07
JP2010532312A5 JP2010532312A5 (enExample) 2012-04-05

Family

ID=39469519

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009548293A Withdrawn JP2010532312A (ja) 2007-01-30 2008-01-30 １−ｈ−ピラゾロ（３，４ｂ）ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用
JP2009548286A Withdrawn JP2010516812A (ja) 2007-01-30 2008-01-30 有糸分裂キナーゼの調節剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009548286A Withdrawn JP2010516812A (ja) 2007-01-30 2008-01-30 有糸分裂キナーゼの調節剤

Country Status (6)

Country Link
US (2) US20110281821A9 (enExample)
EP (2) EP2108020A2 (enExample)
JP (2) JP2010532312A (enExample)
AU (2) AU2008211172A1 (enExample)
CA (2) CA2676658A1 (enExample)
WO (2) WO2008094575A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542966A (ja) * 2010-11-19 2013-11-28 エフ．ホフマン−ラ ロシュ アーゲー ピラゾロピリジンならびにｔｙｋ２阻害剤としてのピラゾロピリジン及びそれらの使用
JP2015516445A (ja) * 2012-05-14 2015-06-11 イースト チャイナ ユニバーシティ オブ サイエンス アンド テクノロジー プテリジノン誘導体およびｅｇｆｒ、ｂｌｋ、ｆｌｔ３の阻害剤としての応用
JP2015518863A (ja) * 2012-05-22 2015-07-06 ジェネンテック， インコーポレイテッド Ｎ−置換ベンズアミドおよび疼痛の処置におけるそれらの使用
JP2021527051A (ja) * 2018-06-05 2021-10-11 ラプト・セラピューティクス・インコーポレイテッド ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008094575A2 (en) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-h-pyrazolo(3,4b)pyrimidine derivatives and their use as modulators of mitotic kinases
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
HUE028347T2 (en) 2008-06-10 2016-12-28 Abbvie Inc Tricyclic compounds
JP5650193B2 (ja) * 2009-03-20 2015-01-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 胸腺腫の治療のためのキナーゼ阻害剤の使用
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
AU2010309882B2 (en) * 2009-10-20 2016-01-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
HUE033099T2 (en) * 2009-12-01 2017-11-28 Abbvie Inc Novel tricyclic compounds
WO2011068899A1 (en) 2009-12-01 2011-06-09 Abbott Laboratories Novel tricyclic compounds
MX2012012328A (es) 2010-04-30 2013-05-06 Cellzome Ltd Compuestos pirazol como inhibidores de jak.
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
WO2013017480A1 (en) * 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) * 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
JP6309519B2 (ja) 2012-07-06 2018-04-11 ジェネンテック， インコーポレイテッド Ｎ置換ベンズアミド及びその使用方法
ES2664782T3 (es) * 2012-11-05 2018-04-23 Nantbio, Inc Derivados que contienen sulfonamida cíclica como inhibidores de la ruta de señalización de hedgehog
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
AU2014356967A1 (en) 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
US10934291B2 (en) 2014-09-25 2021-03-02 Duke University Kinase inhibitors and related methods of use
GB201501115D0 (en) 2015-01-23 2015-03-11 Univ Dundee Compounds
AU2016208528B2 (en) 2015-01-23 2019-02-21 Glaxosmithkline Intellectual Property Development Limited Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
MX386501B (es) 2015-09-28 2025-03-19 Genentech Inc Compuestos terapeuticos y sus metodos de uso
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2019519582A (ja) 2016-06-29 2019-07-11 オリオン コーポレーション ベンゾジオキサン誘導体およびその医薬用途
JP2019532077A (ja) 2016-10-17 2019-11-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
WO2019090272A1 (en) 2017-11-06 2019-05-09 Flx Bio, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN114269734A (zh) 2019-05-08 2022-04-01 维玛兰生物科学公司 Jak抑制剂
WO2020257145A1 (en) * 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
MX2022001702A (es) * 2019-08-08 2022-04-20 Vimalan Biosciences Inc Inhibidores de jak.
EP4090332B1 (en) * 2020-01-15 2025-03-12 KSQ Therapeutics, Inc. Compositions of substituted pyrazolopyrimidines and uses thereof
IL302352A (en) 2020-10-30 2023-06-01 Ksq Therapeutics Inc Solid state forms of substituted pyrazolopyrimidines and uses thereof
CN115403582A (zh) * 2021-05-28 2022-11-29 江苏天士力帝益药业有限公司 Wee1抑制剂及其用途
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN118126043B (zh) * 2022-12-02 2025-01-28 沈阳药科大学 一种高选择性的plk4抑制剂及制备方法和应用
WO2024238570A1 (en) * 2023-05-15 2024-11-21 Aleksia Therapeutics, Inc. Cdk2 inhibitor pyrazolopyrimidine compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010160B1 (ru) * 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
JP2008513463A (ja) * 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
ES2345997T3 (es) * 2005-01-14 2010-10-07 Janssen Pharmaceutica Nv Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular.
AU2006205851A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
WO2008094575A2 (en) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-h-pyrazolo(3,4b)pyrimidine derivatives and their use as modulators of mitotic kinases

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542966A (ja) * 2010-11-19 2013-11-28 エフ．ホフマン−ラ ロシュ アーゲー ピラゾロピリジンならびにｔｙｋ２阻害剤としてのピラゾロピリジン及びそれらの使用
JP2015516445A (ja) * 2012-05-14 2015-06-11 イースト チャイナ ユニバーシティ オブ サイエンス アンド テクノロジー プテリジノン誘導体およびｅｇｆｒ、ｂｌｋ、ｆｌｔ３の阻害剤としての応用
JP2015518863A (ja) * 2012-05-22 2015-07-06 ジェネンテック， インコーポレイテッド Ｎ−置換ベンズアミドおよび疼痛の処置におけるそれらの使用
JP2021527051A (ja) * 2018-06-05 2021-10-11 ラプト・セラピューティクス・インコーポレイテッド ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用

Also Published As

Publication number Publication date
EP2108020A2 (en) 2009-10-14
US20110281821A9 (en) 2011-11-17
AU2008211108A2 (en) 2010-02-18
AU2008211172A2 (en) 2009-12-17
US20100190787A1 (en) 2010-07-29
JP2010516812A (ja) 2010-05-20
CA2676658A1 (en) 2008-08-07
WO2008094602A2 (en) 2008-08-07
US20100249067A1 (en) 2010-09-30
CA2676665A1 (en) 2008-08-07
EP2108019A2 (en) 2009-10-14
WO2008094575A2 (en) 2008-08-07
WO2008094575A3 (en) 2008-12-18
AU2008211108A1 (en) 2008-08-07
WO2008094602A3 (en) 2008-11-13
AU2008211172A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
JP2010532312A (ja) １−ｈ−ピラゾロ（３，４ｂ）ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用
RU2318826C2 (ru) Производные 4-амино-6-фенилпирроло[2,3] пиримидина, обладающие ингибирующим действием в отношении действия тирозинкиназы, их применение и способы получения (варианты)
JP5400626B2 (ja) 置換イミダゾおよびトリアゾロピリミジン類
JP2018533581A (ja) Ｍｎｋ１およびｍｎｋ２のイソインドリン、アザイソインドリン、ジヒドロインデノンならびにジヒドロアザインデノン阻害薬
US10414769B2 (en) 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors
EP3556761B1 (en) Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
JP2017508763A (ja) ５−置換インダゾール−３−カルボキサミドならびにその調製および使用の方法
EA010426B1 (ru) Имидазопиридины и способы их получения и применения
KR20080079262A (ko) 피롤로트리아진 키나제 억제제
PL199615B1 (pl) Pochodne imidazo [1,2-a] pirydyny i pirazolo [2,3-a] pirydyny, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowania
CN102203098A (zh) 作为细胞增殖抑制剂的嘧啶并[5，4-d]嘧啶
CN101616920A (zh) 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
CA2885787A1 (en) Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
CN111153891A (zh) 一种取代苯并咪唑类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
CN101616921A (zh) 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途
US7323469B2 (en) 7H-pyrrolo[2,3-d]pyrimidine derivatives
WO2025035108A2 (en) Inhibitors of parg
JP2020536077A (ja) Ｃｄｋ８／ｃｄｋ１９阻害剤としての新規な［１，６］ナフチリジン化合物及び誘導体
HK40061750A (en) Inhibitors of raf kinases
HK1065483B (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110128

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120530

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20120605